Pharmaron Beijing Co., Ltd. (HKG:3759)

Pharmaron Beijing Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	13,538	12,269	11,533	10,240	7,419	5,114
Other Revenue	6.4	6.4	4.61	26.19	24.48	19.55
Revenue	13,544	12,276	11,538	10,266	7,444	5,134
Revenue Growth (YoY)	14.83%	6.39%	12.39%	37.92%	45.00%	36.63%
Cost of Revenue	8,894	8,091	7,422	6,502	4,768	3,215
Gross Profit	4,650	4,184	4,116	3,764	2,676	1,919
Selling, General & Admin	1,939	1,843	1,859	1,728	1,022	745.89
Research & Development	528.6	469.26	448.28	282.32	151.77	105.35
Other Operating Expenses	179.34	109.7	82.75	66.52	44.04	32.9
Operating Expenses	2,709	2,465	2,426	2,098	1,229	898.95
Operating Income	1,941	1,719	1,690	1,667	1,448	1,020
Interest Expense	-228.12	-243.72	-182.19	-167.31	-83.07	-23.85
Interest & Investment Income	-	615.7	78.95	109.74	371.99	231.55
Currency Exchange Gain (Loss)	31.43	31.43	147	-42.39	-3.16	-131.23
Other Non Operating Income (Expenses)	-35.65	-4.22	-3.61	-2.54	-1.39	-1.35
EBT Excluding Unusual Items	1,708	2,118	1,730	1,564	1,732	1,095
Impairment of Goodwill	-73.54	-73.54	-	-	-	-
Gain (Loss) on Sale of Investments	59.92	1.54	18.75	68.09	119.59	190.86
Gain (Loss) on Sale of Assets	-13.47	-33.67	-9.15	-15.3	-4.25	-7.28
Asset Writedown	0.44	-	-	-	-	-
Other Unusual Items	116.66	78.51	98.48	49.5	63.73	40.72
Pretax Income	1,798	2,091	1,838	1,666	1,911	1,319
Income Tax Expense	387.5	377.1	256.11	314.25	290.92	172.38
Earnings From Continuing Operations	1,411	1,714	1,582	1,352	1,620	1,147
Minority Interest in Earnings	101.64	79.19	19.32	22.47	40.95	25.39
Net Income	1,512	1,793	1,601	1,375	1,661	1,172
Net Income to Common	1,512	1,793	1,601	1,375	1,661	1,172
Net Income Growth	-19.71%	12.01%	16.48%	-17.24%	41.68%	114.25%
Shares Outstanding (Basic)	1,763	1,770	1,772	1,774	1,781	1,779
Shares Outstanding (Diluted)	1,767	1,773	1,775	1,776	1,820	1,785
Shares Change (YoY)	-0.45%	-0.11%	-0.05%	-2.40%	1.97%	20.06%
EPS (Basic)	0.86	1.01	0.90	0.78	0.93	0.66
EPS (Diluted)	0.86	1.01	0.90	0.77	0.91	0.66
EPS Growth	-19.36%	12.13%	16.54%	-15.21%	38.94%	78.46%
Free Cash Flow	800.2	536.02	-111.78	-807.04	-34.78	332.77
Free Cash Flow Per Share	0.45	0.30	-0.06	-0.45	-0.02	0.19
Dividend Per Share	0.200	0.200	0.200	0.200	0.200	0.133
Dividend Growth	-	-	-	-	50.04%	99.85%
Gross Margin	34.33%	34.09%	35.67%	36.67%	35.95%	37.38%
Operating Margin	14.33%	14.01%	14.64%	16.23%	19.45%	19.87%
Profit Margin	11.17%	14.61%	13.88%	13.39%	22.31%	22.84%
Free Cash Flow Margin	5.91%	4.37%	-0.97%	-7.86%	-0.47%	6.48%
EBITDA	2,896	2,583	2,431	2,227	1,852	1,325
EBITDA Margin	21.38%	21.04%	21.07%	21.70%	24.88%	25.81%
D&A For EBITDA	954.87	863.3	741.2	560.76	404.64	304.85
EBIT	1,941	1,719	1,690	1,667	1,448	1,020
EBIT Margin	14.33%	14.01%	14.64%	16.23%	19.45%	19.87%
Effective Tax Rate	21.55%	18.03%	13.94%	18.86%	15.22%	13.06%
Revenue as Reported	13,544	12,276	11,538	10,266	7,444	5,134

Source: S&P Global Market Intelligence. Standard template. Financial Sources.